NPM1 and acute myeloid leukemia: Recently, the prospective, randomized phase III trial Acute Myeloid Leukemia Study Group (AMLSG) 09-09 addressed the clinical benefit of the addition of GO to induction (3 mg/m2 on day 1) and consolidation chemotherapy (3 mg/m2 on day 1 of the first consolidation cycle) in adult patients with NPM1-mutated AML eligible to receive intensive chemotherapy [80].